BI811283
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 20, 2018
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
(PubMed, Br J Haematol)
- No abstract available
Clinical • Combination therapy • Journal • P1 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1